NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
0.8024
Dollar change
-0.0086
Percentage change
-1.06
%
Index- P/E- EPS (ttm)-1.05 Insider Own6.44% Shs Outstand67.75M Perf Week-3.63%
Market Cap53.87M Forward P/E- EPS next Y-0.74 Insider Trans0.00% Shs Float62.81M Perf Month-8.82%
Enterprise Value-16.51M PEG- EPS next Q-0.20 Inst Own26.11% Short Float1.89% Perf Quarter-30.23%
Income-61.69M P/S299.28 EPS this Y20.09% Inst Trans70.39% Short Ratio2.59 Perf Half Y-69.61%
Sales0.18M P/B0.71 EPS next Y-0.44% ROA-54.58% Short Interest1.18M Perf YTD-67.51%
Book/sh1.12 P/C0.76 EPS next 5Y6.48% ROE-62.38% 52W High2.82 -71.50% Perf Year-53.08%
Cash/sh1.06 P/FCF- EPS past 3/5Y13.25% 18.08% ROIC-80.70% 52W Low0.71 12.81% Perf 3Y-47.21%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin-457.26% Volatility3.71% 5.62% Perf 5Y-82.93%
Dividend TTM- EV/Sales-91.72 EPS Y/Y TTM-40.60% Oper. Margin-33206.50% ATR (14)0.07 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.86 Sales Y/Y TTM178.84% Profit Margin-33446.81% RSI (14)37.47 Recom1.38
Dividend Gr. 3/5Y- - Current Ratio5.28 EPS Q/Q52.49% SMA20-0.96% Beta1.29 Target Price4.34
Payout- Debt/Eq0.01 Sales Q/Q-100.00% SMA50-33.46% Rel Volume0.12 Prev Close0.81
Employees74 LT Debt/Eq0.00 EarningsMay 07 BMO SMA200-51.15% Avg Volume457.91K Price0.80
IPONov 08, 2017 Option/ShortYes / Yes EPS/Sales Surpr.29.57% -100.00% Trades Volume56,884 Change-1.06%
Date Action Analyst Rating Change Price Target Change
May-29-25Downgrade Raymond James Strong Buy → Outperform $2
Apr-29-25Initiated Cantor Fitzgerald Overweight $10
Apr-05-23Upgrade Guggenheim Neutral → Buy $8
Feb-28-22Downgrade Guggenheim Buy → Neutral
Oct-28-21Upgrade Raymond James Outperform → Strong Buy $10 → $14
Mar-11-21Upgrade Guggenheim Neutral → Buy $16
Nov-06-20Upgrade SVB Leerink Mkt Perform → Outperform $7 → $10
Oct-08-20Initiated H.C. Wainwright Buy $11
Jun-17-20Initiated BTIG Research Buy $12
Apr-30-20Upgrade Raymond James Mkt Perform → Outperform
Jun-02-25 03:49AM
May-28-25 01:30AM
May-22-25 07:30AM
May-07-25 07:30AM
May-06-25 09:35AM
07:30AM Loading…
Apr-30-25 07:30AM
Apr-02-25 03:33PM
Mar-26-25 09:35AM
Mar-20-25 07:30AM
Mar-19-25 06:00PM
Mar-07-25 08:00AM
Feb-28-25 09:00AM
Feb-25-25 07:30AM
Feb-18-25 04:01PM
Feb-13-25 09:45PM
04:01PM Loading…
04:01PM
Jan-23-25 07:30AM
Jan-16-25 11:05AM
Jan-15-25 12:30PM
Jan-07-25 07:30AM
Dec-20-24 07:30AM
Nov-19-24 06:29PM
Nov-15-24 07:51AM
Nov-12-24 11:00PM
Nov-09-24 07:41AM
Nov-08-24 08:40AM
07:30AM
Oct-31-24 07:30AM
Sep-25-24 07:30AM
Sep-03-24 07:30AM
07:30AM Loading…
Aug-27-24 07:30AM
Aug-08-24 08:50AM
07:30AM
Aug-01-24 07:30AM
Jul-30-24 07:30AM
Jun-24-24 08:02AM
Jun-05-24 12:00PM
May-21-24 02:30PM
May-08-24 11:57AM
07:30AM
Apr-30-24 07:30AM
Apr-24-24 07:30AM
Mar-21-24 11:53AM
08:45AM
07:00AM
Mar-19-24 07:30AM
Feb-22-24 07:30AM
Jan-25-24 07:30AM
Jan-04-24 07:00AM
Dec-01-23 09:55AM
Nov-28-23 09:35AM
Nov-06-23 09:35AM
07:30AM
Nov-01-23 07:30AM
Oct-31-23 07:12PM
Sep-11-23 07:00AM
Sep-01-23 02:38PM
Aug-31-23 10:15AM
Aug-30-23 07:30AM
Aug-10-23 07:30AM
Jun-28-23 07:30AM
Jun-21-23 07:00AM
May-11-23 07:30AM
May-03-23 07:14AM
Apr-18-23 04:01PM
Apr-14-23 04:01PM
Apr-13-23 11:22AM
Apr-11-23 09:08PM
04:00PM
Apr-07-23 10:21AM
Apr-05-23 11:57AM
10:49AM
Apr-04-23 04:14PM
02:55PM
Mar-23-23 08:21AM
Mar-22-23 07:30AM
Jan-05-23 07:30AM
Dec-21-22 07:30AM
Nov-09-22 07:40AM
07:30AM
Sep-29-22 07:30AM
Sep-09-22 07:30AM
Sep-08-22 07:30AM
Sep-07-22 10:54AM
Aug-17-22 12:00PM
Aug-11-22 12:00PM
Aug-05-22 07:00AM
Jul-26-22 03:36PM
07:30AM
Jul-06-22 07:30AM
Jun-29-22 12:02PM
07:30AM
May-17-22 07:30AM
May-13-22 01:55PM
May-12-22 07:30AM
Mar-31-22 02:56PM
07:30AM
Mar-24-22 08:55AM
07:30AM
Mar-17-22 10:03AM
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.